Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
BACKGROUND
Sorafenib and sunitinib are novel small molecule tyrosine kinase inhibitors with multiple targets on tumor cells, which have been demonstrated to be beneficial in the treatment of several carcinomas. Combining the usage of molecular targeted agents and adoptive cellular immunotherapy (ACI) against drug-resistant relapse nasopharyngeal carcinoma which had no standard therapeutic regimen was investigated by our research in order to study whether synergistic effects exist and related mechanisms.


METHODS
Human multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP with high and low expressions of ABCG(2) (abbreviated to ABCG (2) (High) CNE2/DDP and ABCG (2) (Low) CNE2/DDP) cells and NK cells were isolated by magnetic activated cell sorting, and the purity of isolated cells was detected by flow cytometry. mRNA expressions of drug-resistant gene ABCG(2), Bcl-2, MDR1, MRP and MGMT in ABCG (2) (High) CNE2/DDP and ABCG (2) (Low) CNE2/DDP cells were detected by reverse transcription polymerase chain reaction (RT-PCR). Drug sensitivity of two kinds of cells to fluorouracil, cisplatin, vincristine, carboplatin, epirubicin, daunorubicin, paclitaxel, mitomycin, sorafenib, and sunitinib were detected by MTT assay. FCM was used to evaluate the expressions of NKG2D ligands (NKG2DLs,) on target cells before and after incubated with sorafenib and sunitinib. Subsequently, the cytotoxic sensitivity of incubated and un-incubated ABCG (2) (High) CNE2/DDP and ABCG (2) (Low) CNE2/DDP cells to NK cells was measured by CytoTox 96(®) Non-Radioactive Cytotoxicity Assay.


RESULTS
The results revealed that target cells' cytotoxic sensitivity to natural killer (NK) cells increased in association with up-regulation of NKG2DLs on tumor cells after incubation with sorafenib and sunitinib. Furthermore, up-regulation in sunitinib group was much higher than in sorafenib group when it came to the expressions of NKG2DLs on tumor cells. For another, ABCG (2) (High) CNE2/DDP was much more sensitive to the regulation than ABCG (2) (Low) CNE2/DDP.


CONCLUSIONS
Our research revealed for the first time that sorafenib and sunitinib could up-regulate NKG2DLs on tumor cells resulting in markedly increased tumor cells cytotoxic sensitivity to NK cells, which suggested that combining usage of molecular targeted agents and ACI may result in great benefits in clinical practice for the therapy-resistant cases and drug-resistant relapse.
Huang
Yuxian
Y
Department of Hematology, Zhujiang Hospital, Southern Medical University, 510282, Guangzhou, China, hyx6610@163.com.
Wang
Yang
Y
Li
Yuhua
Y
Guo
Kunyuan
K
He
Yanjie
Y
D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000032:analysis*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001557:Benzenesulfonates / Q000494:pharmacology*; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D019008:Drug Resistance, Neoplasm; D058851:GPI-Linked Proteins / Q000032:analysis; D006801:Humans; D018189:Immunomagnetic Separation; D016219:Immunotherapy, Adoptive; D007211:Indoles / Q000494:pharmacology*; D036341:Intercellular Signaling Peptides and Proteins / Q000032:analysis*; D007694:Killer Cells, Natural / Q000276:immunology; D016014:Linear Models; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D009363:Neoplasm Proteins / Q000032:analysis*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077157:Sorafenib; D000077210:Sunitinib
C116614:ABCG2 protein, human; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D058851:GPI-Linked Proteins; D007211:Indoles; D036341:Intercellular Signaling Peptides and Proteins; D009363:Neoplasm Proteins; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; C423230:ULBP2 protein, human; C423229:ULBP3 protein, human; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib
Mol Ther. 2007 Jun;15(6):1065-71
17375068
J Leukoc Biol. 2007 Nov;82(5):1322-31
17711975
Cancer Metastasis Rev. 2007 Mar;26(1):39-57
17323127
Cancer Res. 2006 Apr 15;66(8):3959-62
16618710
Cancer Res. 2006 Dec 15;66(24):11851-8
17178882
Clin Cancer Res. 2007 Nov 1;13(21):6419-28
17962339
Nat Immunol. 2001 Apr;2(4):293-9
11276199
Immunol Rev. 2006 Dec;214:130-42
17100881
Cancer Res. 2008 Mar 1;68(5):1546-54
18316620
Science. 2001 Oct 19;294(5542):534-6
11567108
J Surg Oncol. 2008 Jun 15;97(8):701-7
18493921
Cell Immunol. 2006 Jan;239(1):22-30
16630603
Clin Cancer Res. 1998 Nov;4(11):2859-68
9829753
Exp Hematol. 2007 Oct;35(10):1522-6
17889720
Nat Immunol. 2008 May;9(5):503-10
18425107
Br J Cancer. 2008 Aug 5;99(3):387-91
18665178
Scand J Immunol. 2008 May;67(5):441-7
18312485
Science. 1999 Jul 30;285(5428):730-2
10426994
Mediators Inflamm. 2006;2006(4):46957
17047292
Crit Rev Oncol Hematol. 2000 Apr;34(1):1-25
10781746
Cancer Res. 2002 Nov 1;62(21):6178-86
12414645
Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31
18192256
Hum Pathol. 2008 Jun;39(6):837-45
18400250